Genmab A/S (NASDAQ:GMAB) Shares Sold by Bank of America Corp DE

Bank of America Corp DE lowered its position in Genmab A/S (NASDAQ:GMAB - Free Report) by 55.0% during the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 474,858 shares of the company's stock after selling 579,588 shares during the period. Bank of America Corp DE owned 0.07% of Genmab A/S worth $9,910,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in GMAB. Renaissance Technologies LLC lifted its stake in shares of Genmab A/S by 7.8% in the fourth quarter. Renaissance Technologies LLC now owns 1,926,150 shares of the company's stock worth $40,199,000 after buying an additional 139,722 shares in the last quarter. First Trust Advisors LP raised its holdings in Genmab A/S by 18.0% in the 4th quarter. First Trust Advisors LP now owns 1,644,288 shares of the company's stock valued at $34,316,000 after acquiring an additional 251,241 shares during the last quarter. Brandywine Global Investment Management LLC purchased a new position in Genmab A/S in the 4th quarter worth approximately $33,804,000. Marshall Wace LLP boosted its holdings in shares of Genmab A/S by 162.2% during the 4th quarter. Marshall Wace LLP now owns 1,122,296 shares of the company's stock worth $23,422,000 after purchasing an additional 694,243 shares during the last quarter. Finally, Northern Trust Corp boosted its holdings in shares of Genmab A/S by 18.8% during the 4th quarter. Northern Trust Corp now owns 599,381 shares of the company's stock worth $12,509,000 after purchasing an additional 94,858 shares during the last quarter. Institutional investors and hedge funds own 7.07% of the company's stock.

Analyst Ratings Changes

A number of equities analysts recently commented on GMAB shares. Leerink Partners upgraded Genmab A/S from a "market perform" rating to an "outperform" rating and set a $27.00 price objective on the stock in a research report on Thursday, February 13th. Sanford C. Bernstein cut shares of Genmab A/S from a "market perform" rating to an "underperform" rating in a research report on Tuesday, April 1st. Leerink Partnrs upgraded shares of Genmab A/S from a "hold" rating to a "strong-buy" rating in a research report on Thursday, February 13th. William Blair raised shares of Genmab A/S from a "market perform" rating to an "outperform" rating in a research note on Tuesday, March 11th. Finally, BNP Paribas raised shares of Genmab A/S from a "strong sell" rating to a "hold" rating in a research note on Tuesday, February 11th. One research analyst has rated the stock with a sell rating, three have issued a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $39.17.

Genmab A/S Stock Performance

Shares of Genmab A/S stock traded up $0.13 on Thursday, reaching $21.32. The company had a trading volume of 685,051 shares, compared to its average volume of 1,137,299. The firm's 50 day moving average price is $19.88 and its two-hundred day moving average price is $20.65. Genmab A/S has a 52-week low of $17.24 and a 52-week high of $28.96. The firm has a market cap of $13.67 billion, a PE ratio of 12.25, a PEG ratio of 2.65 and a beta of 1.04.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last announced its earnings results on Thursday, May 8th. The company reported $0.31 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.23 by $0.08. Genmab A/S had a return on equity of 16.78% and a net margin of 36.30%. The company had revenue of $715.00 million for the quarter, compared to analyst estimates of $5.17 billion. As a group, sell-side analysts predict that Genmab A/S will post 1.45 EPS for the current year.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.